Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Germline variants associated with toxicity to immune checkpoint blockade.
Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Groha S, et al. Among authors: naranbhai v. Nat Med. 2022 Dec;28(12):2584-2591. doi: 10.1038/s41591-022-02094-6. Epub 2022 Dec 16. Nat Med. 2022. PMID: 36526723 Free PMC article.
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
Taylor CA, Watson RA, Tong O, Ye W, Nassiri I, Gilchrist JJ, de Los Aires AV, Sharma PK, Koturan S, Cooper RA, Woodcock VK, Jungkurth E, Shine B, Coupe N, Payne MJ, Church DN, Naranbhai V, Groha S, Emery P, Mankia K, Freedman ML, Choueiri TK, Middleton MR, Gusev A, Fairfax BP. Taylor CA, et al. Among authors: naranbhai v. Nat Med. 2022 Dec;28(12):2592-2600. doi: 10.1038/s41591-022-02095-5. Epub 2022 Dec 16. Nat Med. 2022. PMID: 36526722 Free PMC article.
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Mureithi MW, Poole D, Naranbhai V, Reddy S, Mkhwanazi NP, Sibeko S, Werner L, Abdool Karim Q, Abdool Karim S, Ndung'u T, Altfeld M; CAPRISA004 Trial Group. Mureithi MW, et al. Among authors: naranbhai v. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):124-7. doi: 10.1097/QAI.0b013e31824f53a9. J Acquir Immune Defic Syndr. 2012. PMID: 22362152 Free PMC article.
Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004.
Naranbhai V, Samsunder N, Sandler NG, Roque A, Abdool Karim Q, Ndungʼu T, Carr WH, Altfeld M, Douek DC, Abdool Karim SS; CAPRISA 004 Trial Team. Naranbhai V, et al. J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):294-8. doi: 10.1097/QAI.0b013e31828e604b. J Acquir Immune Defic Syndr. 2013. PMID: 23481666 Free PMC article. Clinical Trial.
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
Chopera DR, Mann JK, Mwimanzi P, Omarjee S, Kuang XT, Ndabambi N, Goodier S, Martin E, Naranbhai V, Karim SA, Karim QA, Brumme ZL, Ndung'u T, Williamson C, Brockman MA; CAPRISA 004 TRAPS Team. Chopera DR, et al. Among authors: naranbhai v. PLoS One. 2013 Aug 28;8(8):e71758. doi: 10.1371/journal.pone.0071758. eCollection 2013. PLoS One. 2013. PMID: 24015191 Free PMC article.
109 results